Metronomic chemotherapy is well tolerated, less toxic and as effective as standard chemotherapy. Results from the XeNa trial: a randomized phase 2 trial combining vinorelbine and capecitabine in the treatment of advanced HER2 negative breast cancer

A. S. Brems-Eskildsen; S Linnet; Adam Andrzej Luczak; H. Nielsen; P. Vestlev; E. H. Jacobsen; J. Neimann; C. B. Jensen; T. Dongsgaard; S. T. Langkjer

doi:10.1016/S0959-8049(16)31962-1

Metronomic chemotherapy is well tolerated, less toxic and as effective as standard chemotherapy. Results from the XeNa trial: a randomized phase 2 trial combining vinorelbine and capecitabine in the treatment of advanced HER2 negative breast cancer

A. S. Brems-Eskildsen, S Linnet, Adam Andrzej Luczak, H. Nielsen, P. Vestlev, E. H. Jacobsen, J. Neimann, C. B. Jensen, T. Dongsgaard, S. T. Langkjer

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Originalsprog	Engelsk
Artikelnummer	384
Tidsskrift	European Journal of Cancer
Vol/bind	57
Udgave nummer	Suppl. 2
Sider (fra-til)	S110
ISSN	0959-8049
DOI	https://doi.org/10.1016/S0959-8049(16)31962-1
Status	Udgivet - 2016
Begivenhed	10th European Breast Cancer Conference - Amsterdam, Holland Varighed: 9 mar. 2016 → 11 mar. 2016 Konferencens nummer: 10

Konference

Konference	10th European Breast Cancer Conference
Nummer	10
Land/Område	Holland
By	Amsterdam
Periode	09/03/2016 → 11/03/2016

Adgang til dokumentet

10.1016/S0959-8049(16)31962-1

AUB Link

Søg efter materialet i Aalborg Universitetsbiblioteks søgemaskine

Citationsformater

Brems-Eskildsen, A. S., Linnet, S., Luczak, A. A., Nielsen, H., Vestlev, P., Jacobsen, E. H., Neimann, J., Jensen, C. B., Dongsgaard, T., & Langkjer, S. T. (2016). Metronomic chemotherapy is well tolerated, less toxic and as effective as standard chemotherapy. Results from the XeNa trial: a randomized phase 2 trial combining vinorelbine and capecitabine in the treatment of advanced HER2 negative breast cancer. European Journal of Cancer, 57(Suppl. 2), S110. Artikel 384. https://doi.org/10.1016/S0959-8049(16)31962-1

Brems-Eskildsen, A. S. ; Linnet, S ; Luczak, Adam Andrzej et al. / Metronomic chemotherapy is well tolerated, less toxic and as effective as standard chemotherapy. Results from the XeNa trial : a randomized phase 2 trial combining vinorelbine and capecitabine in the treatment of advanced HER2 negative breast cancer. I: European Journal of Cancer. 2016 ; Bind 57, Nr. Suppl. 2. s. S110.

@article{b0fc84416f9f4953a86a078b3be6bbb6,

title = "Metronomic chemotherapy is well tolerated, less toxic and as effective as standard chemotherapy. Results from the XeNa trial: a randomized phase 2 trial combining vinorelbine and capecitabine in the treatment of advanced HER2 negative breast cancer",

author = "Brems-Eskildsen, {A. S.} and S Linnet and Luczak, {Adam Andrzej} and H. Nielsen and P. Vestlev and Jacobsen, {E. H.} and J. Neimann and Jensen, {C. B.} and T. Dongsgaard and Langkjer, {S. T.}",

year = "2016",

doi = "10.1016/S0959-8049(16)31962-1",

language = "English",

volume = "57",

pages = "S110",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Pergamon Press",

number = "Suppl. 2",

note = "10th European Breast Cancer Conference ; Conference date: 09-03-2016 Through 11-03-2016",

}

Brems-Eskildsen, AS, Linnet, S, Luczak, AA, Nielsen, H, Vestlev, P, Jacobsen, EH, Neimann, J, Jensen, CB, Dongsgaard, T & Langkjer, ST 2016, 'Metronomic chemotherapy is well tolerated, less toxic and as effective as standard chemotherapy. Results from the XeNa trial: a randomized phase 2 trial combining vinorelbine and capecitabine in the treatment of advanced HER2 negative breast cancer', European Journal of Cancer, bind 57, nr. Suppl. 2, 384, s. S110. https://doi.org/10.1016/S0959-8049(16)31962-1

Metronomic chemotherapy is well tolerated, less toxic and as effective as standard chemotherapy. Results from the XeNa trial: a randomized phase 2 trial combining vinorelbine and capecitabine in the treatment of advanced HER2 negative breast cancer. / Brems-Eskildsen, A. S.; Linnet, S; Luczak, Adam Andrzej et al.
I: European Journal of Cancer, Bind 57, Nr. Suppl. 2, 384, 2016, s. S110.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

TY - ABST

T1 - Metronomic chemotherapy is well tolerated, less toxic and as effective as standard chemotherapy. Results from the XeNa trial

T2 - 10th European Breast Cancer Conference

AU - Brems-Eskildsen, A. S.

AU - Linnet, S

AU - Luczak, Adam Andrzej

AU - Nielsen, H.

AU - Vestlev, P.

AU - Jacobsen, E. H.

AU - Neimann, J.

AU - Jensen, C. B.

AU - Dongsgaard, T.

AU - Langkjer, S. T.

N1 - Conference code: 10

PY - 2016

Y1 - 2016

U2 - 10.1016/S0959-8049(16)31962-1

DO - 10.1016/S0959-8049(16)31962-1

M3 - Conference abstract in journal

SN - 0959-8049

VL - 57

SP - S110

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - Suppl. 2

M1 - 384

Y2 - 9 March 2016 through 11 March 2016

ER -

Brems-Eskildsen AS, Linnet S, Luczak AA, Nielsen H, Vestlev P, Jacobsen EH et al. Metronomic chemotherapy is well tolerated, less toxic and as effective as standard chemotherapy. Results from the XeNa trial: a randomized phase 2 trial combining vinorelbine and capecitabine in the treatment of advanced HER2 negative breast cancer. European Journal of Cancer. 2016;57(Suppl. 2):S110. 384. doi: 10.1016/S0959-8049(16)31962-1